Skip to main content

IMDx to Develop Tests on Abbott's m2000 Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IMDx reported on Thursday that it has entered into an agreement with Abbott to design, develop, and manufacture assays using Abbott's FDA-approved m2000 platform.

Privately held IMDx will also bring the assays through the regulatory process.

Financial and other terms of the multi-year deal were not disclosed.

The tests covered by the agreement include assays for Clostridium difficile, vancomycin-resistant Enterococci; Group B Streptococci; Influenza A/Influenza B, and Herpes simplex virus types 1 and 2. Two other tests, for determining the viral load for Epstein-Barr virus and for BK virus, will be commercialized outside the US, Cambridge, Mass.-based IMDx said.

The company uses its proprietary bioinformatics process to create its tests, ensuring products that are optimized and in silico verified, it said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.